Clinical trial enrollment during first course of gynecologic cancer treatment and survival
Wafa Khadraoui(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ashley S. Felix(Wake Forest University), Robert Dood(Huntsman Cancer Institute), Jesse J. Plascak(The Ohio State University), Caitlin E. Meade(The Ohio State University), Jennifer A. Sinnott(Florida State University), Floor Backes(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Autumn Carey(The Ohio State University), Britton Trabert(St. Elizabeth's Hospital)
Cited by 1
Related Papers
Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium
|Journal of Clinical Oncology|2016|517
Cardiovascular Disease Risk Among Cancer Survivors
|Journal of the American College of Cardiology|2022|299
Amount and Intensity of Leisure-Time Physical Activity and Lower Cancer Risk
|Journal of Clinical Oncology|2019|289
A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk
|JNCI Journal of the National Cancer Institute|2017|103
Racial and Ethnic Disparities in Clinical Trial Enrollment Among Women With Gynecologic Cancer
|JAMA Network Open|2023|41